Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic

Katherine M. James, Clayton T. Cowl, Jon C Tilburt, Pamela S. Sinicrope, Marguerite E. Robinson, Katrin R. Frimannsdottir, Kristina Tiedje, Barbara A. Koenig

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

OBJECTIVE: To assess the impact of direct-to-consumer (DTC) predictive genomic risk information on perceived risk and worry in the context of routine clinical care. PATIENTS AND METHODS: Patients attending a preventive medicine clinic between June 1 and December 18, 2009, were randomly assigned to receive either genomic risk information from a DTC product plus usual care (n=74) or usual care alone (n=76). At intervals of 1 week and 1 year after their clinic visit, participants completed surveys containing validated measures of risk perception and levels of worry associated with the 12 conditions assessed by the DTC product. RESULTS: Of 345 patients approached, 150 (43%) agreed to participate, 64 (19%) refused, and 131 (38%) did not respond. Compared with those receiving usual care, participants who received genomic risk information initially rated their risk as higher for 4 conditions (abdominal aneurysm [P=.001], Graves disease [P=.04], obesity [P=.01], and osteoarthritis [P=.04]) and lower for one (prostate cancer [P=.02]). Although differences were not significant, they also reported higher levels of worry for 7 conditions and lower levels for 5 others. At 1 year, there were no significant differences between groups. CONCLUSION: Predictive genomic risk information modestly influences risk perception and worry. The extent and direction of this influence may depend on the condition being tested and its baseline prominence in preventive health care and may attenuate with time.

Original languageEnglish (US)
Pages (from-to)933-940
Number of pages8
JournalMayo Clinic Proceedings
Volume86
Issue number10
DOIs
StatePublished - 2011

Fingerprint

Health
Preventive Health Services
Preventive Medicine
Graves Disease
Ambulatory Care
Osteoarthritis
Aneurysm
Prostatic Neoplasms
Obesity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. / James, Katherine M.; Cowl, Clayton T.; Tilburt, Jon C; Sinicrope, Pamela S.; Robinson, Marguerite E.; Frimannsdottir, Katrin R.; Tiedje, Kristina; Koenig, Barbara A.

In: Mayo Clinic Proceedings, Vol. 86, No. 10, 2011, p. 933-940.

Research output: Contribution to journalArticle

James, Katherine M. ; Cowl, Clayton T. ; Tilburt, Jon C ; Sinicrope, Pamela S. ; Robinson, Marguerite E. ; Frimannsdottir, Katrin R. ; Tiedje, Kristina ; Koenig, Barbara A. / Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. In: Mayo Clinic Proceedings. 2011 ; Vol. 86, No. 10. pp. 933-940.
@article{b7cbeda57c7d49bf934dcb643efff0ae,
title = "Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic",
abstract = "OBJECTIVE: To assess the impact of direct-to-consumer (DTC) predictive genomic risk information on perceived risk and worry in the context of routine clinical care. PATIENTS AND METHODS: Patients attending a preventive medicine clinic between June 1 and December 18, 2009, were randomly assigned to receive either genomic risk information from a DTC product plus usual care (n=74) or usual care alone (n=76). At intervals of 1 week and 1 year after their clinic visit, participants completed surveys containing validated measures of risk perception and levels of worry associated with the 12 conditions assessed by the DTC product. RESULTS: Of 345 patients approached, 150 (43{\%}) agreed to participate, 64 (19{\%}) refused, and 131 (38{\%}) did not respond. Compared with those receiving usual care, participants who received genomic risk information initially rated their risk as higher for 4 conditions (abdominal aneurysm [P=.001], Graves disease [P=.04], obesity [P=.01], and osteoarthritis [P=.04]) and lower for one (prostate cancer [P=.02]). Although differences were not significant, they also reported higher levels of worry for 7 conditions and lower levels for 5 others. At 1 year, there were no significant differences between groups. CONCLUSION: Predictive genomic risk information modestly influences risk perception and worry. The extent and direction of this influence may depend on the condition being tested and its baseline prominence in preventive health care and may attenuate with time.",
author = "James, {Katherine M.} and Cowl, {Clayton T.} and Tilburt, {Jon C} and Sinicrope, {Pamela S.} and Robinson, {Marguerite E.} and Frimannsdottir, {Katrin R.} and Kristina Tiedje and Koenig, {Barbara A.}",
year = "2011",
doi = "10.4065/mcp.2011.0190",
language = "English (US)",
volume = "86",
pages = "933--940",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic

AU - James, Katherine M.

AU - Cowl, Clayton T.

AU - Tilburt, Jon C

AU - Sinicrope, Pamela S.

AU - Robinson, Marguerite E.

AU - Frimannsdottir, Katrin R.

AU - Tiedje, Kristina

AU - Koenig, Barbara A.

PY - 2011

Y1 - 2011

N2 - OBJECTIVE: To assess the impact of direct-to-consumer (DTC) predictive genomic risk information on perceived risk and worry in the context of routine clinical care. PATIENTS AND METHODS: Patients attending a preventive medicine clinic between June 1 and December 18, 2009, were randomly assigned to receive either genomic risk information from a DTC product plus usual care (n=74) or usual care alone (n=76). At intervals of 1 week and 1 year after their clinic visit, participants completed surveys containing validated measures of risk perception and levels of worry associated with the 12 conditions assessed by the DTC product. RESULTS: Of 345 patients approached, 150 (43%) agreed to participate, 64 (19%) refused, and 131 (38%) did not respond. Compared with those receiving usual care, participants who received genomic risk information initially rated their risk as higher for 4 conditions (abdominal aneurysm [P=.001], Graves disease [P=.04], obesity [P=.01], and osteoarthritis [P=.04]) and lower for one (prostate cancer [P=.02]). Although differences were not significant, they also reported higher levels of worry for 7 conditions and lower levels for 5 others. At 1 year, there were no significant differences between groups. CONCLUSION: Predictive genomic risk information modestly influences risk perception and worry. The extent and direction of this influence may depend on the condition being tested and its baseline prominence in preventive health care and may attenuate with time.

AB - OBJECTIVE: To assess the impact of direct-to-consumer (DTC) predictive genomic risk information on perceived risk and worry in the context of routine clinical care. PATIENTS AND METHODS: Patients attending a preventive medicine clinic between June 1 and December 18, 2009, were randomly assigned to receive either genomic risk information from a DTC product plus usual care (n=74) or usual care alone (n=76). At intervals of 1 week and 1 year after their clinic visit, participants completed surveys containing validated measures of risk perception and levels of worry associated with the 12 conditions assessed by the DTC product. RESULTS: Of 345 patients approached, 150 (43%) agreed to participate, 64 (19%) refused, and 131 (38%) did not respond. Compared with those receiving usual care, participants who received genomic risk information initially rated their risk as higher for 4 conditions (abdominal aneurysm [P=.001], Graves disease [P=.04], obesity [P=.01], and osteoarthritis [P=.04]) and lower for one (prostate cancer [P=.02]). Although differences were not significant, they also reported higher levels of worry for 7 conditions and lower levels for 5 others. At 1 year, there were no significant differences between groups. CONCLUSION: Predictive genomic risk information modestly influences risk perception and worry. The extent and direction of this influence may depend on the condition being tested and its baseline prominence in preventive health care and may attenuate with time.

UR - http://www.scopus.com/inward/record.url?scp=80053479421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053479421&partnerID=8YFLogxK

U2 - 10.4065/mcp.2011.0190

DO - 10.4065/mcp.2011.0190

M3 - Article

VL - 86

SP - 933

EP - 940

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -